Insider Selling: Zynex Inc. (ZYXI) CEO Sells 100,000 Shares of Stock

Zynex Inc. (OTCMKTS:ZYXI) CEO Thomas Sandgaard sold 100,000 shares of the company’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $6.76, for a total transaction of $676,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Thomas Sandgaard also recently made the following trade(s):

  • On Tuesday, May 21st, Thomas Sandgaard sold 9,045 shares of Zynex stock. The stock was sold at an average price of $8.00, for a total transaction of $72,360.00.
  • On Wednesday, May 15th, Thomas Sandgaard sold 15,403 shares of Zynex stock. The stock was sold at an average price of $7.50, for a total transaction of $115,522.50.
  • On Friday, May 10th, Thomas Sandgaard sold 39,684 shares of Zynex stock. The stock was sold at an average price of $7.25, for a total transaction of $287,709.00.
  • On Monday, April 8th, Thomas Sandgaard sold 83,194 shares of Zynex stock. The stock was sold at an average price of $4.77, for a total transaction of $396,835.38.
  • On Thursday, April 4th, Thomas Sandgaard sold 17,206 shares of Zynex stock. The stock was sold at an average price of $4.75, for a total transaction of $81,728.50.
  • On Wednesday, March 20th, Thomas Sandgaard sold 48,008 shares of Zynex stock. The stock was sold at an average price of $4.40, for a total transaction of $211,235.20.
  • On Monday, March 18th, Thomas Sandgaard sold 51,992 shares of Zynex stock. The stock was sold at an average price of $4.49, for a total transaction of $233,444.08.

Shares of OTCMKTS ZYXI traded down $0.12 during trading on Thursday, reaching $7.28. 87,900 shares of the company traded hands, compared to its average volume of 72,380. The company has a market cap of $237.32 million, a PE ratio of 33.09 and a beta of 1.05. Zynex Inc. has a 52-week low of $2.40 and a 52-week high of $8.00.

Zynex (OTCMKTS:ZYXI) last released its quarterly earnings data on Tuesday, April 30th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.02. The firm had revenue of $9.20 million for the quarter, compared to analysts’ expectations of $8.45 million. Zynex had a net margin of 33.33% and a return on equity of 152.81%. As a group, equities research analysts forecast that Zynex Inc. will post 0.28 EPS for the current fiscal year.

Several brokerages recently issued reports on ZYXI. Zacks Investment Research upgraded shares of Zynex from a “sell” rating to a “hold” rating in a research note on Thursday, May 23rd. B. Riley reiterated a “buy” rating on shares of Zynex in a research note on Friday, February 22nd. Finally, ValuEngine upgraded shares of Zynex from a “hold” rating to a “buy” rating in a research note on Friday, February 8th.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Acadian Asset Management LLC purchased a new stake in shares of Zynex during the first quarter valued at $215,000. WealthTrust Axiom LLC purchased a new stake in shares of Zynex during the first quarter valued at $132,000. O Shaughnessy Asset Management LLC purchased a new stake in shares of Zynex during the first quarter valued at $118,000. Sigma Planning Corp purchased a new stake in shares of Zynex during the first quarter valued at $63,000. Finally, ExodusPoint Capital Management LP purchased a new stake in shares of Zynex during the first quarter valued at $45,000. 0.05% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Zynex Inc. (ZYXI) CEO Sells 100,000 Shares of Stock” was first posted by Rockland Register and is the property of of Rockland Register. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://rocklandregister.com/2019/05/30/thomas-sandgaard-sells-100000-shares-of-zynex-inc-zyxi-stock.html.

About Zynex

Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.

Featured Story: What is a put option?

Insider Buying and Selling by Quarter for Zynex (OTCMKTS:ZYXI)

Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.